Addressing unmet needs for inherited neuromuscular diseases

Addressing unmet needs for inherited neuromuscular diseases
angilma1

/by
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis ranks first in 2024 Access to Medicine Index

Novartis ranks first in 2024 Access to Medicine Index
arcticnovartis

  • The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics
  • Novartis malaria access plans, widespread registration of products in LMICs, and inclusive business model to improve access to products in multiple countries were all highlighted as Best Practice across the industry
  • Novartis has risen three places to secure the top spot on the 2024 Access to Medicine Index
/by
Official partner of the Eurovision Song Contest 2025

Official partner of the Eurovision Song Contest 2025
weberfr8

/by
Official partner of the Eurovision Song Contest 2025

Official partner of the Eurovision Song Contest 2025
weberfr8

/by
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben

Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR

/by
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance

Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial 

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial 
arcticnovartis

  • New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1
  • Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function – vs. patients’ historic rapid decline1
  • Fabhalta also showed a favorable safety profile with no new safety signals1
/by